PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: targeted combo therapy enters Mid-Stage trial
Disease control Not yet recruitingThis study tests a new drug called IBI343 combined with other treatments for people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific marker (CLDN18.2). The goal is to see if the combination is safe and shrinks tumors. About 389 adults w…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
Gene test may unlock better cancer treatments for Hard-to-Treat tumors
Knowledge-focused Not yet recruitingThis study looks at whether doing broad gene testing early, instead of later, can help find more effective treatments for people with advanced liver, breast, or pancreatic cancers. About 360 adults with poor-prognosis cancers will be randomly assigned to early or standard gene te…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated May 16, 2026 22:28 UTC